Baxter International Inc (BAX) Quote - XNYS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Baxter Plans to Acquire Hillrom; Baxter Shares Fairly Valued

Senior Equity Analyst Julie Utterback

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA | Sep 2, 2021

Baxter announced plans to acquire Hillrom for $12.4 billion in enterprise value ($10.5 billion in equity value, or $156 per share) in a transaction that is expected to close in early 2022. We view the combination positively and expect to keep our narrow economic moat rating intact. We see Baxter shares as about fairly valued; at first glance, as we update our model and recognize recent cash flows, we would expect any valuation increase to be limited to the midsingle digits.

Read Full Analysis

Company Profile

Business Description

Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2020 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while the acute therapies segment (6%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (23% of sales) sells IV pumps, administrative sets, and solutions while the nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (18% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostatic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.

Contact

One Baxter Parkway
Deerfield, IL, 60015

T +1 224 948-2000

Global_CORP_Investor_Relations@baxter.com

Sector Healthcare

Industry Medical Instruments & Supplies

Most Recent Earnings Jun 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type Classic Growth

Employees 50,000

Related

Is It Time to Sell These 5 Stocks?

These names suffered double-digit losses in October. Should you hold on?

Susan Dziubinski

Stock Strategist

Home Dialysis to Benefit These Undervalued Providers

DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.

Advisor Insights

Enduring Philosophy

At Aristotle, the emphasis is on long-term ownership.

Friday Five: Time to Tune In to Media Stocks

Overblown concerns over cable cord-cutters could be opening up opportunities in the media sector. Plus, Ackman's sweet tooth for Mondelez, Priceline still attractive, and more.

Stock Strategist

Biogen's Drop Looks Like Overreaction

We've lowered our fair value estimate, but the shares remain attractive.

Stock Strategist

Competition Rising for Baxalta

The newly independent firm still has a narrow moat, however.

Stock Strategist

Baxter's Headwinds Mostly Temporary

The company faces near-term challenges after the split, but we still like its moat.

Michael Waterhouse

Quarter-End Insights

Health Care: A Few Stocks Still Offer Upside

Despite the sector looking slightly overvalued, we still see stocks with attractive valuations across the different industries.

Quarter-End Insights

Stock Market Outlook: Pick Your Spots Carefully

Interest-rate fears bring utility and real estate valuations in line, but the broader market still looks fully valued.

Matthew Coffina

Baxter's Spin-Off Strategy Is Promising

Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen.

Quarter-End Insights

Health Care: 3 Picks in a More Expensive Sector

Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price

Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.

Quarter-End Insights

Health Care: A Strong Run, but Some Stocks Still Look Undervalued

While the sector looks slightly overvalued overall, we still see several stocks that offer attractive valuations across the different industries.

5 Issues Still on Investors' Plates

Central Bank recipes, leftover housing disappointments, and full valuations may still cause indigestion for investors, says Morningstar markets editor Jeremy Glaser.

Finding a Margin of Safety in a Fully Valued Market

These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

Quarter-End Insights

Health Care: Some Healthy Bargains Still Remain

While the sector looks fairly valued overall, we still see several stocks that offer attractive valuations across the different industries, including pharmacy benefit managers.

The Friday Five

This week: Financial-services firms post lukewarm earnings, two tech giants strike a deal, Time Warner turns down a foxy offer, and more.

A Portfolio Checkup in 6 Steps

In this special midyear presentation, Morningstar's Christine Benz demonstrates how to gauge the viability of your current plan, evaluate positioning, troubleshoot risk factors, and much more.

Quarter-End Insights

Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

Stock Strategist

Moats and Growth Drivers Look Solid for Post-Split Baxter

Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.